Article
Cell Biology
Weiliang Jiang, Congying Chen, Li Huang, Jie Shen, Lijuan Yang
Summary: The study revealed that overexpression of GATA4 exacerbates inflammation-induced pancreatic cancer cell invasion and growth, while silencing of GATA4 attenuates these processes. Inflammation-driven cancer progression is dependent on GATA4 expression and is mediated through the STAT3 and NF-kappa B signaling pathways.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Richard Drexler, Mirco Kuchler, Kim C. Wagner, Tim Reese, Bernd Feyerabend, Moritz Kleine, Karl J. Oldhafer
Summary: The Hippo pathway is more active in non-metastasized patients compared to metastasized patients, with upregulation of certain components in the latter group. High pYAP expression is associated with favorable overall survival (OS) and disease-free survival (DFS).
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Nausika Betriu, Juan Bertran-Mas, Anna Andreeva, Carlos E. Semino
Summary: Syndecans, a subfamily of proteoglycans, play critical roles in various physiological processes and have implications in disease progression. Their interactions with other macromolecules contribute to normal cellular functions and disease pathogenesis.
Article
Biochemistry & Molecular Biology
Siyuan Chen, Bo Ning, Jinwen Song, Zihan Yang, Li Zhou, Zhiji Chen, Linhong Mao, Hongtao Liu, Qingliang Wang, Song He, Zhihang Zhou
Summary: Acidic microenvironment promotes proliferation and metastasis of pancreatic cancer cells by inhibiting AMPK/Hippo signaling and upregulating MMP1 expression.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Review
Oncology
Siddharth Mehra, Nilesh Deshpande, Nagaraj Nagathihalli
Summary: Pancreatic cancer has a low survival rate and strong resistance to treatment, making targeted inhibition of the PI3K/Akt/mTOR pathway crucial for reducing tumor burden and improving survival. Targeted therapy against PI3K signaling has shown significant impact on modulating tumor-stromal-immune interactions within the microenvironment of pancreatic cancer.
Article
Biochemistry & Molecular Biology
Maria Mortoglou, Francesc Miralles, Elif Damla Arisan, Alwyn Dart, Stipo Jurcevic, Sigrun Lange, Pinar Uysal-Onganer
Summary: This study investigated the role of miR-21 in cancer stem cells (CSCs) and its association with the aggressiveness of PDAC. Knockout of miR-21 resulted in reversed expressions of CSC markers and suppressed cellular invasion and proliferation. These findings suggest that miR-21 is involved in the stemness of PDAC cells, may play roles in mesenchymal transition, and serves as a novel functional biomarker for PDAC aggressiveness.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Hiromitsu Hayashi, Norio Uemura, Liu Zhao, Kazuki Matsumura, Hiroki Sato, Yuta Shiraishi, Hideo Baba
Summary: PDAC is a lethal type of cancer with key genetic mutations. Dysregulation of the Hippo signaling pathway and activation of YAP/TAZ are closely associated with PDAC development and may serve as therapeutic targets.
FRONTIERS IN ONCOLOGY
(2021)
Editorial Material
Oncology
Samuel J. S. Rubin, Raoul S. Sojwal, John Gubatan, Stephan Rogalla
Summary: This review discusses the pro- and anticancer immune responses in the tumor immune microenvironment of pancreatic ductal adenocarcinoma (PDAC) and explores their potential for the development of novel therapeutic approaches.
Article
Multidisciplinary Sciences
Yuanxin Tang, Sheng Zhang, Jiazi Li, Chunli Wu, Qing Fan
Summary: Pancreatic Ductal Adenocarcinoma (PDAC) is a deadly disease with increasing death rates and no effective treatment. The study suggests that ID1 is a critical determinant of PDAC development and progression, serving as a potential malignant biomarker for the disease.
SCIENTIFIC REPORTS
(2022)
Review
Cell Biology
Tianyi Zhang, Yanxian Ren, Pengfei Yang, Jufang Wang, Heng Zhou
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with a high deposition of extracellular matrix (ECM) and poor prognosis. ECM proteins derived from tumor cells reduce the effectiveness of conventional cancer treatment and contribute to tumor progression and metastasis. Cancer-associated fibroblasts (CAFs) in the ECM are promising targets for novel anti-tumor interventions.
CELL DEATH & DISEASE
(2022)
Article
Cell Biology
Zhihua Ye, Yingyu Yang, Ying Wei, Lamei Li, Xinyi Wang, Junkai Zhang
Summary: This study identified PCDH1 as a new prognostic marker in pancreatic ductal adenocarcinoma (PDAC) patients. PCDH1 expression was upregulated in PDAC tissues and was associated with tumor invasion depth and lymph node metastasis. Mechanistically, PCDH1 enhanced p65 nuclear localization by interacting with KPNB1, activating the NF-kappa B signaling pathway and promoting PDAC progression.
CELL DEATH & DISEASE
(2022)
Review
Pharmacology & Pharmacy
Jinlu Liu, Wenbi Wu, Qing Zhu, Hong Zhu
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly tumor characterized by a tumor microenvironment consisting of fibroblasts and immunosuppressive cells. Traditional therapies are limited by poor drug delivery efficiency, immunosuppressive tumor microenvironment, and adverse effects. Therefore, there is an urgent need for effective and safe treatments. In recent years, hydrogel-based therapies have been developed as potential therapeutic options for PDAC, offering controlled drug delivery with excellent biocompatibility and high drug load capacity.
Review
Biochemistry & Molecular Biology
Sylvia S. W. Ng, Laura A. A. Dawson
Summary: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease in oncology. Surgery is the only potential curative treatment. Palliative multiagent chemotherapy is the first-line treatment for patients with locally advanced/unresectable or metastatic disease. Chemoradiation or stereotactic ablative radiotherapy can improve locoregional control and symptom control for these patients.
Article
Oncology
Shuang Lu, Hong Sun Kim, Yubo Cao, Karan Bedi, Lili Zhao, Ishwarya Venkata Narayanan, Brian Magnuson, Yumei Gu, Jing Yang, Zhujun Yi, Sepideh Babaniamansour, Sargis Shameon, Chang Xu, Michelle T. Paulsen, Ping Qiu, Sivakumar Jeyarajan, Mats Ljungman, Dafydd Thomas, Yali Dou, Howard Crawford, Marina Pasca di Magliano, Kai Ge, Bo Yang, Jiaqi Shi
Summary: In this study, a novel signaling axis mediated by KMT2D linking TGF-beta to the activin A pathway was discovered. Loss of KMT2D induces the expression and secretion of activin A, which activates a noncanonical p38 MAPK-mediated pathway to enhance tumor invasion and metastasis in pancreatic cancer.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Biochemistry & Molecular Biology
Valentina Giansante, Gianmarco Stati, Silvia Sancilio, Emanuela Guerra, Saverio Alberti, Roberta Di Pietro, Joerg D. Hoheisel
Summary: Pancreatic cancer is the seventh leading cause of cancer-related death, and its incidence is increasing each year. The low relative survival rate and challenges of heterogeneity and tumor microenvironment in pancreatic cancer have emphasized the need for novel therapeutic strategies. This review focuses on the role of necroptosis in pancreatic cancer progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Cristina Montero-Conde, Luis J. Leandro-Garcia, Xu Chen, Gisele Oler, Sergio Ruiz-Llorente, Mabel Ryder, Inigo Landa, Francisco Sanchez-Vega, Konnor La, Ronald A. Ghossein, Dean F. Bajorin, Jeffrey A. Knauf, Jesse D. Riordan, Adam J. Dupuy, James A. Fagin
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2017)
Article
Multidisciplinary Sciences
Iwei Yeh, Ursula E. Lang, Emeline Durieux, Meng Kian Tee, Aparna Jorapur, A. Hunter Shain, Veronique Haddad, Daniel Pissaloux, Xu Chen, Lorenzo Cerroni, Robert L. Judson, Philip E. LeBoit, Timothy H. McCalmont, Boris C. Bastian, Arnaud de la Fouchardiere
NATURE COMMUNICATIONS
(2017)
Article
Oncology
Fa-Xing Yu, Jing Luo, Jung-Soon Mo, Guangbo Liu, Young Chul Kim, Zhipeng Meng, Ling Zhao, Gholam Peyman, Hong Ouyang, Wei Jiang, Jiagang Zhao, Xu Chen, Liangfang Zhang, Cun-Yu Wang, Boris C. Bastian, Kang Zhang, Kun-Liang Guan
Article
Oncology
Michelle Croyle, Nagako Akeno, Jeffrey A. Knauf, Doriano Fabbro, Xu Chen, Jacqueline E. Baumgartner, Heidi A. Lane, James A. Fagin
Article
Biochemistry & Molecular Biology
X. Chen, Q. Wu, L. Tan, D. Porter, M. J. Jager, C. Emery, B. C. Bastian
Article
Biochemistry & Molecular Biology
X. Chen, J. M. Makarewicz, J. A. Knauf, L. K. Johnson, J. A. Fagin
Article
Multidisciplinary Sciences
Xu Chen, Norisato Mitsutake, Krista LaPerle, Nagako Akeno, Pat Zanzonico, Valerie A. Longo, Shin Mitsutake, Edna T. Kimura, Hartmut Geiger, Eugenio Santos, Hans G. Wendel, Aime Franco, Jeffrey A. Knauf, James A. Fagin
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2009)
Article
Biochemistry & Molecular Biology
Jiafang Ma, Li Weng, Boris C. Bastian, Xu Chen
Summary: The study identified the CYSLTR2 -> GNAQ/11 -> PLC beta signaling pathway as a key driver of uveal melanoma proliferation, with the PKC/RasGRP3/MAPK signaling branch being essential. Inhibition of the MAPK branch, but not the FAK branch, synergized with inhibition of the proximal cascade, providing a blueprint for combination therapy. All oncogenic signaling could be suppressed by the GNAQ/11 inhibitor YM-254890, highlighting its potential for treating neoplastic disorders with G alpha q pathway mutations.
Article
Oncology
Xu Chen, Qiuxia Wu, Philippe Depeille, Peirong Chen, Sophie Thornton, Helen Kalirai, Sarah E. Coupland, Jeroen P. Roose, Boris C. Bastian
Article
Multidisciplinary Sciences
M Carter, X Chen, B Slowinska, S Minnerath, S Glickstein, L Shi, F Campagne, H Weinstein, ME Ross
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2005)
Article
Biochemistry & Molecular Biology
X Chen, MD Resh
JOURNAL OF BIOLOGICAL CHEMISTRY
(2002)
Article
Biochemistry & Molecular Biology
X Chen, MD Resh
JOURNAL OF BIOLOGICAL CHEMISTRY
(2001)